Launch of two new automated assays

Immunodiagnostic Systems Holdings plc.

29 March 2018

Launch of two new automated assays

Launch of IDS SHBG assay - new addition to the IDS Fertility portfolio

Launch of the IDS ACE assay - first biochemistry test for the IDS Automated System

Immunodiagnostic Systems Holdings plc (IDS), a specialty solution provider to the clinical laboratory diagnostic market, today launched the IDS SHBG and the IDS ACE assays in the European market for use with the IDS Automated System.  

The IDS SHBG assay measures the levels of sex hormone binding protein in blood samples. Measurement of SHBG concentrations can be used to assist in the diagnosis of androgen disorders such as primary and secondary hypogonadism, delayed or precocious puberty, impotence in males, polycystic ovaries in females, and adrenogenital syndromes. This assay extends the IDS Fertility portfolio, and complements the recently launched Total Testosterone, Free Testosterone and 17-OH Progesterone assays. These assays allow laboratories to improve their workflow with the IDS automated platform.

The commercialisation of the IDS ACE assay marks the first biochemistry test on the IDS Automated System. Angiotensin-Converting Enzyme (ACE) blood tests can be used for monitoring the therapeutic treatment of diagnosed Sarcoidosis. Sarcoidosis is a multisystem inflammatory disease of unknown cause that predominantly affects the lungs and intrathoracic lymph nodes. Apart from this inflammatory disease, ACE levels may also be altered in conditions such as tuberculosis, multiple sclerosis and cystic fibrosis.

The Global market size for SHBG and ACE testing is estimated to be around $10-15 million each worldwide.

For further information:

Immunodiagnostic Systems Holdings plc Tel: +44 (0) 191 519 0660

Jaap Stuut, Chief Executive Officer

Paul Martin, Group Finance Director

Peel Hunt LLP Tel: +44 (0) 20 7418 8900

James Steel

Oliver Jackson